Chromatin accessibility changes at intergenic regions are associated with ovarian cancer drug resistance.
View/ Open
Date
2021-06-05ICR Author
Author
Gallon, J
Loomis, E
Curry, E
Martin, N
Brody, L
Garner, I
Brown, R
Flanagan, JM
Type
Journal Article
Metadata
Show full item recordAbstract
BACKGROUND: Resistance to DNA damaging chemotherapies leads to cancer treatment failure and poor patient prognosis. We investigated how genomic distribution of accessible chromatin sites is altered during acquisition of cisplatin resistance using matched ovarian cell lines from high grade serous ovarian cancer (HGSOC) patients before and after becoming clinically resistant to platinum-based chemotherapy. RESULTS: Resistant lines show altered chromatin accessibility at intergenic regions, but less so at gene promoters. Clusters of cis-regulatory elements at these intergenic regions show chromatin changes that are associated with altered expression of linked genes, with enrichment for genes involved in the Fanconi anemia/BRCA DNA damage response pathway. Further, genome-wide distribution of platinum adducts associates with the chromatin changes observed and distinguish sensitive from resistant lines. In the resistant line, we observe fewer adducts around gene promoters and more adducts at intergenic regions. CONCLUSIONS: Chromatin changes at intergenic regulators of gene expression are associated with in vivo derived drug resistance and Pt-adduct distribution in patient-derived HGSOC drug resistance models.
Collections
Research team
Medicine (Brown Epigenetic Therapy)
Medicine (Brown Epigenetic Therapy)
Language
eng
Date accepted
2021-05-17
License start date
2021-06-05
Citation
Clinical epigenetics, 2021, 13 (1), pp. 122 - ?
Publisher
BMC